Zhou Q, Zhang MM, Liu M et al (2021) LncRNA XIST sponges miR-199a-3p to modulate the Sp1/LRRK2 signal pathway to accelerate Parkinsons disease progression
What Drug Manufacturers Are Demanding Novo Nordisk and Eli Lilly have sent cease-and-desist letters to compounding pharmacies, weight loss clinics, medical spas, and other entities involved in the compounding of GLP-1 medicines
Originally developed in Russia, Semax is believed to modulate brain-derived neurotrophic factor (BDNF) and influence neurotransmitter systems
1 Weight loss results: Semaglutide 0.5 mg: -4.6 kg vs dulaglutide 0.75 mg: -2.3 kg Semaglutide 1.0 mg: -6.5 kg vs dulaglutide 1.5 mg: -3.0 kg Treatment difference: approximately double the weight loss with semaglutide at both dose levels Blood sugar control was also superior with semaglutide at all dose comparisons: Cardiovascular outcomes Both medications have demonstrated cardiovascular benefits, though in different trials
Mechanism of Interaction Laboratory studies have characterized the compound as interacting with GHRH receptor pathways in anterior pituitary tissue
Treatment of polycystic ovary syndrome in adults
